Edition:
United Kingdom

Fate Therapeutics Inc (FATE.OQ)

FATE.OQ on NASDAQ Stock Exchange Global Market

6.61USD
8:27pm GMT
Change (% chg)

$-0.40 (-5.71%)
Prev Close
$7.01
Open
$7.12
Day's High
$7.13
Day's Low
$6.50
Volume
107,185
Avg. Vol
98,252
52-wk High
$7.25
52-wk Low
$2.54

Chart for

About

Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from... (more)

Overall

Beta: 1.51
Market Cap(Mil.): $170.63
Shares Outstanding(Mil.): 41.42
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 84.57 16.44
EPS (TTM): -- -- --
ROI: -- 3.42 10.61
ROE: -- 5.38 14.21

BRIEF-Fate Therapeutics announces issuance of U.S. patent covering use of viral transduction enhancers in gene therapy

* Fate Therapeutics announces issuance of U.S. patent covering use of viral transduction enhancers in gene therapy

16 Aug 2017

BRIEF-Fate Therapeutics Q2 ‍net loss per common share $0.23​

* Fate Therapeutics reports second quarter 2017 financial results

14 Aug 2017

Earnings vs. Estimates